Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
Rhea-AI Summary
Anika (NASDAQ: ANIK) will issue its first quarter 2026 financial results before the market opens on Wednesday, April 29, 2026. A conference call to discuss results and business highlights will follow at 8:30 a.m. ET.
Investors can join by dialing 1-800-717-1738 (domestic) or 1-646-307-1865 (international) with conference ID 82141. A live audio webcast and presentation materials will be available and archived in the Investor Relations section of Anika's website at www.anika.com.
Positive
- None.
Negative
- None.
News Market Reaction – ANIK
In the Apr 16 session, ANIK gained 0.72%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Q4/FY 2025 results | Positive | +16.9% | Reported Q4 and FY 2025 results with margin expansion and guidance. |
| Feb 12 | Results scheduling | Neutral | +1.5% | Announced timing and call details for Q4 and year-end 2025 results. |
| Nov 05 | Q3 2025 results | Negative | +2.3% | Reported Q3 2025 revenue decline but highlighted key product and licensing advances. |
| Oct 23 | Results scheduling | Neutral | +3.7% | Pre-announced Q3 2025 release date and earnings call logistics. |
| Jul 30 | Q2 2025 results | Negative | -27.4% | Detailed Q2 2025 revenue decline and missed trial endpoints with revised outlook. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-related news has usually led to positive price reactions, with only one negative divergence despite mixed fundamental results in prior quarters.
Over the past year, Anika’s earnings and earnings-related announcements, including Q2–Q4 2025 results and multiple pre-release notices, have typically been followed by positive stock moves. Events on Jul 30, 2025 and Nov 5, 2025 showed that even when revenue declined or results were mixed, strategic updates on Hyalofast, Cingal, and channel growth often coincided with constructive trading. Today’s Q1 2026 release scheduling fits this pattern of consistent communication around quarterly results.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEDFORD, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2026 financial results before the opening of the market on Wednesday, April 29, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 82141. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.anika.com. The call will be archived and accessible on the same website shortly after its conclusion.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Executive Director, Corporate Development and Investor Relations
investorrelations@anika.com
